Denali Therapeutics, Inc. (DNLI)
22.28
-0.52
(-2.28%)
USD |
NASDAQ |
Sep 04, 16:00
22.28
0.00 (0.00%)
After-Hours: 20:00
Denali Therapeutics SG&A Expense (TTM) : 144.74M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 144.74M |
| March 31, 2026 | 140.72M |
| December 31, 2025 | 136.56M |
| September 30, 2025 | 127.16M |
| June 30, 2025 | 116.63M |
| March 31, 2025 | 109.56M |
| December 31, 2024 | 105.44M |
| September 30, 2024 | 100.15M |
| June 30, 2024 | 100.52M |
| March 31, 2024 | 101.45M |
| December 31, 2023 | 103.35M |
| September 30, 2023 | 102.10M |
| June 30, 2023 | 100.04M |
| March 31, 2023 | 95.07M |
| December 31, 2022 | 90.48M |
| September 30, 2022 | 88.72M |
| June 30, 2022 | 84.78M |
| March 31, 2022 | 82.66M |
| December 31, 2021 | 79.06M |
| September 30, 2021 | 75.29M |
| Date | Value |
|---|---|
| June 30, 2021 | 71.78M |
| March 31, 2021 | 66.71M |
| December 31, 2020 | 60.33M |
| September 30, 2020 | 53.21M |
| June 30, 2020 | 48.62M |
| March 31, 2020 | 49.72M |
| December 31, 2019 | 46.48M |
| September 30, 2019 | 46.65M |
| June 30, 2019 | 44.27M |
| March 31, 2019 | 36.09M |
| December 31, 2018 | 32.35M |
| September 30, 2018 | 26.37M |
| June 30, 2018 | 21.31M |
| March 31, 2018 | 17.98M |
| December 31, 2017 | 15.68M |
| September 30, 2017 | 13.66M |
| June 30, 2017 | 13.00M |
| March 31, 2017 | 9.433M |
| December 31, 2016 | 6.159M |
| September 30, 2016 | 3.113M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 172.57M |
| Oncolytics Biotech, Inc. | 16.62M |
| Sangamo Therapeutics, Inc. | 31.64M |
| Sarepta Therapeutics, Inc. | 436.74M |
| Anixa Biosciences, Inc. | 6.118M |